Our policy in the Medical Programs Department of the National Psoriasis Foundation (NPF) is to ensure balance, independence, objectivity, and scientific rigor in all our educational programs.  Anyone presenting or participating in the planning of any NPF CME programs is expected to disclose to the Medical Programs Department any real or apparent affiliation(s) within the past 12 months that may have a direct bearing on the subject matter of the continuing medical education program.  The intent of this policy is to ensure continuing medical education programs that are free of commercial interests.

The following faculty and planning committee have disclosed the following relationships with commercial interests:

Faculty:

Joel Gelfand, MD
In the previous 12 months, Dr. Gelfand served as a consultant for  BMS, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Boehringer Ingelheim,  Janssen, Novartis Corp , Celgene, Ortho Dermatologics, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics and Novartis. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma. Dr Gelfand is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology.

 

Planning Committee:

Andi Agnew has disclosed no relevant financial relationships with any commercial interests.